Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
News|Articles|November 1, 2019
Maintaining Sterility and Stability of Injectables
Author(s)Pharmaceutical Technology Editors
On Wednesday Nov. 6, 2019, Dr. Derek Duncan from Lighthouse Instruments will summarize the current state of container closure integrity testing (CCIT) in the bio/pharma industry and will outline a framework for the development of a holistic testing strategy.
Advertisement
On Wednesday Nov. 6, 2019, Dr. Derek Duncan from Lighthouse Instruments will summarize the current state of container closure integrity testing (CCIT) in the bio/pharma industry and will outline a framework for the development of a holistic testing strategy.
CCIT is important in the maintenance of stability and sterility of injectable products, particularly in light of the fact that any defects in injectables that cause a sterile leak in the vial are not always necessarily defects that will be detected by visual inspection. New regulatory guidance on CCIT is creating a shift in the way in which testing is being approached, with traditional methods being described as associated with probabilistic outcomes.
Additionally, as a result of new regulatory guidance, testing should now be performed throughout the product lifecycle. There are deterministic CCIT methods available that are based on non-destructive analytical measurements, which when coupled with a risk-based approach can be used to generate statistical data for container closure integrity that may be useful in making decisions about inspection processes for commercial manufacturing.
Container Closure Integrity Testing of Sterile Pharmaceutical Product Throughout the Product Life Cycle
Wednesday Nov. 6, 2019
15:50–16:20
InnoPack & P-MEC Theatre (110D50)
Advertisement
Related to this article
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement